Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AFM24 Monotherapy in Advanced Solid Tumors
NCT04259450Phase 2Terminated
- Sponsor
- Affimed
- Start
- Apr 2020
- Primary completion
- Jul 2023
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 5
01
Overview
Phase 2, open-label trial of AFM24 in solid tumor, clear cell renal cell carcinoma (ccRCC), non-small cell lung cancer (NSCLC) and 1 more (10 arms), sponsored by Affimed. Primary endpoints: Number of Subjects With Dose Limiting Toxicities and Overall Response Rate at 16 weeks. Started Apr 2020; status: terminated.
02
Drugs
AFM24
03
Conditions
solid tumorclear cell renal cell carcinoma (ccRCC)non-small cell lung cancer (NSCLC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT04259450.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04259450.